Ikonisys Announces the Completion of a Private Placement to Speed up Growth Following Recent Pivotal Deals

Regulatory News:

Ikonisys SA (ISIN Code: FR00140048X2 / Ticker: ALIKO) (Paris:ALIKO), a company specializing in the early and accurate detection of cancer with a unique and fully-automated solution for medical diagnostic labs (the “Issuer”), today announced that it raised €1m, via a private placement with Italian private and institutional investors, in order to strengthen its financial resources in view of the implementation of the distribution agreement with Biocare Medical¹ and the future integration of Hospitex International² .

The net proceeds of this issue, amounting to €1m, will provide the Issuer with additional resources to:

- support the launch of the commercialization of its solutions by Biocare Medical in the USA, and

- expand the commercialization of Hospitex’s products initially in Europe and at a later stage in the USA.

Alessandro Mauri, Chief Financial Officer of Ikonisys declared: “We are very pleased to announce the successful completion of an operation that provides us with additional resources to support the dynamic growth expected in 2024. Our recent deals have deeply reshaped the profile of the Company. In the framework of our partnership with Biocare Medical to expand global distribution of our Ikoniscope solutions, we have now visibility over the next 2 years and the revenue forecast is set between €5 and €7 million by this time. Furthermore, the strategic acquisition of Hospitex positions us globally across the entire value chain of pathology labs, from slide preparation to analysis. This move not only strengthens our short-term perspective of profitability but also leverages strong technological, commercial and operational synergies. As we look forward to these promising developments for the year to come, we would like to thank our new investors for their confidence in the strategic direction of our Company.”

Legal terms of the Capital Increase

The implementation of this capital increase, carried out with cancellation of shareholders' subscription rights through a private placement, was approved by the Board of Directors of the Issuer at its meeting held on December 27, 2023 (the "Capital Increase").

The new shares will be issued on the basis of the 8^th resolution of the Issuer's shareholders' meeting held on June 28, 2023. The settlement-delivery of the new shares will take place on January 2, 2024.

The Capital Increase did not require the approval of a notice (“prospectus”) by the Autorité des marchés financiers (the “AMF”).

Main terms of the Capital Increase